Hexarelin

—

evidence score

gh secretagogue

Research Only

Evidence Level C

examorelinEP-23905

Hexarelin is a synthetic ghrelin receptor agonist/GHRP with strong GH-releasing activity. It has been explored in cardiometabolic and endocrine research, but is not approved for routine therapeutic use. Tolerance (desensitization) with prolonged exposure is a practical limitation in many protocols.

Safety & legal caution

Educational database only — not medical or legal advice.

Safety

Can elevate prolactin/cortisol more than highly selective GHRPs in some users.
May worsen insulin sensitivity in susceptible individuals with chronic high exposure.
Data quality is moderate-to-low for long-term enhancement contexts.

Legal / compliance

Generally not approved for routine prescribing in US/EU enhancement contexts.
Likely prohibited in tested sport.

Current literature links

Cardiovascular effects of growth hormone secretagogues including hexarelin(2000)Hexarelin endocrine effects and receptor pharmacology(2002)

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

Phase II

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Dosing

Typical

200 mcg

100 mcgRange400 mcg

Frequency1–2x/day, cyclical usage commonly used

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~1 hour (peptide), endocrine effects longer

OnsetWithin minutes for GH pulse

Duration2–4 hours endocrine pulse window

Routes

subcutaneous

intramuscular

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(24%)—

Quality(24%)—

Sample Size(12%)—

Consistency(14%)—

Replication(8%)—

Recency(18%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Hexarelin is currently categorized as a gh secretagogue compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

GHS-R1a agonism causing pulsatile GH release with downstream IGF-1 increases

Practical Context

Strongest current signals

No indexed study summaries yet.